dc.contributor.author | Baird, RD | |
dc.contributor.author | Sandhu, S | |
dc.contributor.author | Yap, T | |
dc.contributor.author | Massard, C | |
dc.contributor.author | Papadatos-Pastos, D | |
dc.contributor.author | Olmos, D | |
dc.contributor.author | Dukes, J | |
dc.contributor.author | Grainger, P | |
dc.contributor.author | Pope, L | |
dc.contributor.author | De Bono, J | |
dc.coverage.spatial | Brussels, BELGIUM | |
dc.date.accessioned | 2018-06-26T10:50:22Z | |
dc.date.issued | 2011-05-01 | |
dc.identifier | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000290610100066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9 | |
dc.identifier.citation | ANNALS OF ONCOLOGY, 2011, 22 pp. 41 - 41 (1) | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1936 | |
dc.format.extent | 41 - 41 (1) | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | OXFORD UNIV PRESS | |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Oncology | |
dc.title | BASELINE CIRCULATING TUMOR CELL COUNTS SIGNIFICANTLY ENHANCE A PROGNOSTIC SCORE FOR PATIENTS PARTICIPATING IN PHASE I ONCOLOGY TRIALS | |
dc.type | Other | |
rioxxterms.licenseref.startdate | 2011-05-01 | |
rioxxterms.type | Other | |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | |
pubs.finish-date | 2011-05-07 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.publication-status | Published | |
pubs.start-date | 2011-05-05 | |
pubs.volume | 22 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicine Drug Development Unit (de Bono) | en_US |
icr.researchteam | Prostate Cancer Targeted Therapy Group | en_US |
dc.contributor.icrauthor | De Bono, Johann | en |
dc.contributor.icrauthor | Yap, Timothy | en |